Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases.

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Hansen Ree A, Edwin B, Nygaard V, Flatmark K.

Oncotarget. 2017 Jul 18;8(44):76290-76304. doi: 10.18632/oncotarget.19350. eCollection 2017 Sep 29.

2.

Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K.

ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017.

3.

Th17 Polarization under Hypoxia Results in Increased IL-10 Production in a Pathogen-Independent Manner.

Volchenkov R, Nygaard V, Sener Z, Skålhegg BS.

Front Immunol. 2017 Jun 19;8:698. doi: 10.3389/fimmu.2017.00698. eCollection 2017.

4.

Reply to Towfic and others' letter to the editor.

Nygaard V, Rødland EA, Hovig E.

Biostatistics. 2017 Jul 1;18(3):586-587. doi: 10.1093/biostatistics/kxx001. No abstract available.

PMID:
28334081
5.

Subtype-specific micro-RNA expression signatures in breast cancer progression.

Haakensen VD, Nygaard V, Greger L, Aure MR, Fromm B, Bukholm IR, Lüders T, Chin SF, Git A, Caldas C, Kristensen VN, Brazma A, Børresen-Dale AL, Hovig E, Helland Å.

Int J Cancer. 2016 Sep 1;139(5):1117-28. doi: 10.1002/ijc.30142. Epub 2016 May 9.

6.

Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors.

Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L.

Oncotarget. 2016 Apr 12;7(15):19997-20015. doi: 10.18632/oncotarget.7671.

7.

Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses.

Nygaard V, Rødland EA, Hovig E.

Biostatistics. 2016 Jan;17(1):29-39. doi: 10.1093/biostatistics/kxv027. Epub 2015 Aug 13.

8.

Metabolic reprogramming supports the invasive phenotype in malignant melanoma.

Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Øyjord T, Risa Ø, Nygaard V, Mælandsmo GM, Prasmickaite L.

Cancer Lett. 2015 Sep 28;366(1):71-83. doi: 10.1016/j.canlet.2015.06.006. Epub 2015 Jun 18.

PMID:
26095603
9.

Melanoma brain colonization involves the emergence of a brain-adaptive phenotype.

Nygaard V, Prasmickaite L, Vasiliauskaite K, Clancy T, Hovig E.

Oncoscience. 2014 Jan 10;1(1):82-94. eCollection 2014.

10.

Identifying pathogenic processes by integrating microarray data with prior knowledge.

Nygård S, Reitan T, Clancy T, Nygaard V, Bjørnstad J, Skrbic B, Tønnessen T, Christensen G, Hovig E.

BMC Bioinformatics. 2014 Apr 24;15:115. doi: 10.1186/1471-2105-15-115.

11.

Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties.

Bettum IJ, Vasiliauskaite K, Nygaard V, Clancy T, Pettersen SJ, Tenstad E, Mælandsmo GM, Prasmickaite L.

Cancer Lett. 2014 Mar 1;344(1):28-39. doi: 10.1016/j.canlet.2013.10.036. Epub 2013 Nov 8.

PMID:
24215866
12.

The Genomic HyperBrowser: an analysis web server for genome-scale data.

Sandve GK, Gundersen S, Johansen M, Glad IK, Gunathasan K, Holden L, Holden M, Liestøl K, Nygård S, Nygaard V, Paulsen J, Rydbeck H, Trengereid K, Clancy T, Drabløs F, Ferkingstad E, Kalas M, Lien T, Rye MB, Frigessi A, Hovig E.

Nucleic Acids Res. 2013 Jul;41(Web Server issue):W133-41. doi: 10.1093/nar/gkt342. Epub 2013 Apr 30.

13.

The differential disease regulome.

Sandve GK, Gundersen S, Rydbeck H, Glad IK, Holden L, Holden M, Liestøl K, Clancy T, Drabløs F, Ferkingstad E, Johansen M, Nygaard V, Tøstesen E, Frigessi A, Hovig E.

BMC Genomics. 2011 Jul 7;12:353. doi: 10.1186/1471-2164-12-353.

14.

Immunological network signatures of cancer progression and survival.

Clancy T, Pedicini M, Castiglione F, Santoni D, Nygaard V, Lavelle TJ, Benson M, Hovig E.

BMC Med Genomics. 2011 Mar 31;4:28. doi: 10.1186/1755-8794-4-28.

15.

The Genomic HyperBrowser: inferential genomics at the sequence level.

Sandve GK, Gundersen S, Rydbeck H, Glad IK, Holden L, Holden M, Liestøl K, Clancy T, Ferkingstad E, Johansen M, Nygaard V, Tøstesen E, Frigessi A, Hovig E.

Genome Biol. 2010;11(12):R121. doi: 10.1186/gb-2010-11-12-r121. Epub 2010 Dec 23.

16.

Methods for quantitation of gene expression.

Nygaard V, Hovig E.

Front Biosci (Landmark Ed). 2009 Jan 1;14:552-69. Review.

PMID:
19273085
17.

Cell sampling and global nucleic acid amplification.

Nygaard V, Hovig E.

SEB Exp Biol Ser. 2008;61:17-36. Review. No abstract available.

PMID:
18709735
18.

Validation of oligoarrays for quantitative exploration of the transcriptome.

Nygaard V, Liu F, Holden M, Kuo WP, Trimarchi J, Ohno-Machado L, Cepko CL, Frigessi A, Glad IK, Wiel MA, Hovig E, Lyng H.

BMC Genomics. 2008 May 30;9:258. doi: 10.1186/1471-2164-9-258.

19.
20.

Limitations of mRNA amplification from small-size cell samples.

Nygaard V, Holden M, Løland A, Langaas M, Myklebost O, Hovig E.

BMC Genomics. 2005 Oct 27;6:147.

Supplemental Content

Loading ...
Support Center